 The PAMPA study is evaluating whether Goosalcumab, an anti-Illinois-23P19 antibody, can prevent the development of psoriatic arthritis, PSA, in patients with psoriasis who are at increased risk for PSA progression. This study will also assess the effectiveness of Goosalcumab in reducing musculoskeletal-powered Doppler ultrasound, PDUS, abnormalities. This article was offered by Joseph F. Merola, Leahy Eder, Proton Raman, and others.